Stockscreener 앱 받기
250.50
0.66%
-1.66
시간 외 거래:
252.00
1.50
+0.60%
전일 마감가:
$252.16
열려 있는:
$255.62
하루 거래량:
770.65K
Relative Volume:
1.08
시가총액:
$12.89B
수익:
$708.24M
순이익/손실:
$-188.30M
주가수익비율:
-66.99
EPS:
-3.7392
순현금흐름:
$-70.99M
1주 성능:
-1.29%
1개월 성능:
+10.16%
6개월 성능:
+70.41%
1년 성능:
+143.46%
1일 변동 폭
$247.34
$260.19
1주일 범위
$247.34
$260.19
52주 변동 폭
$96.09
$260.19
Axsome Therapeutics Inc Stock (AXSM) Company Profile
명칭
Axsome Therapeutics Inc
전화
(212) 332-3241
주소
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
250.50 | 12.89B | 708.24M | -188.30M | -70.99M | -3.7392 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-01 | 개시 | B. Riley Securities | Buy |
| 2025-09-03 | 재개 | Wells Fargo | Overweight |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-06-03 | 개시 | Oppenheimer | Outperform |
| 2025-04-07 | 개시 | Jefferies | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-12-31 | 재확인 | Mizuho | Outperform |
| 2024-09-03 | 개시 | Wells Fargo | Overweight |
| 2024-08-06 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-07-22 | 개시 | Needham | Buy |
| 2024-04-29 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | 개시 | Robert W. Baird | Outperform |
| 2024-02-06 | 개시 | UBS | Buy |
| 2024-01-25 | 개시 | RBC Capital Mkts | Outperform |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-08-08 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-01-05 | 개시 | Piper Sandler | Neutral |
| 2022-11-01 | 개시 | Loop Capital | Buy |
| 2022-09-07 | 재개 | Mizuho | Buy |
| 2021-08-10 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | 개시 | Berenberg | Buy |
| 2021-01-08 | 개시 | Jefferies | Buy |
| 2020-12-16 | 개시 | Mizuho | Buy |
| 2020-09-29 | 개시 | BofA Securities | Underperform |
| 2020-09-10 | 개시 | Morgan Stanley | Overweight |
| 2020-04-28 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-14 | 개시 | Cowen | Outperform |
| 2019-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-17 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-16 | 재확인 | Guggenheim | Buy |
| 2019-10-16 | 개시 | Guggenheim | Buy |
| 2019-09-18 | 개시 | William Blair | Outperform |
| 2019-05-28 | 개시 | SunTrust | Buy |
| 2019-05-23 | 재확인 | H.C. Wainwright | Buy |
| 2019-04-08 | 개시 | SVB Leerink | Outperform |
| 2019-03-15 | 재확인 | H.C. Wainwright | Buy |
| 2016-10-03 | 재개 | Brean Capital | Buy |
| 2015-12-15 | 개시 | Cantor Fitzgerald | Buy |
| 2015-12-14 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Axsome Therapeutics Inc 주식(AXSM)의 최신 뉴스
Virtu Financial LLC Invests $2.84 Million in Axsome Therapeutics, Inc. $AXSM - MarketBeat
12,955 Shares in Axsome Therapeutics, Inc. $AXSM Purchased by Seven Fleet Capital Management LP - MarketBeat
Axsome Therapeutics Inc (AXSM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Axsome Therapeutics Inc (AXSM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Axsome Therapeutics Inc (AXSM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
AXSM Stock Clocks Best Day In About 4 Months On FDA Greenlight For Alzheimer’s Drug - Stocktwits
Axsome Therapeutics (NASDAQ:AXSM) Hits New 1-Year High on Analyst Upgrade - MarketBeat
Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month - Yahoo Finance
Cormorant Asset Management LP Sells 25,000 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
BVF Inc. IL Sells 441,000 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics Inc (AXSM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Axsome Therapeutics Inc (AXSM) Institutional Confidence - TradingKey
Axsome Therapeutics Inc (AXSM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
AXSM Maintains Buy Rating by TD Cowen -- Price Target Raised to $300 - GuruFocus
Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $300.00 at TD Cowen - MarketBeat
TD Cowen raises Axsome Therapeutics price target on Auvelity growth By Investing.com - Investing.com India
Hypercharge Announces Issuance of Equity Grants - GlobeNewswire Inc.
Cynosure Group LLC Sells 4,369 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Upgraded to "Strong-Buy" at Truist Financial - MarketBeat
Sofinnova Investments Inc. Has $2.24 Million Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
3 Under-the-Radar Stocks to Buy and Hold for a Decade - The Globe and Mail
Axsome Therapeutics Inc (AXSM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Axsome presents data on narcolepsy treatments at sleep conference By Investing.com - Investing.com South Africa
Axsome presents data on narcolepsy treatments at sleep conference - Investing.com
Axsome Therapeutics Presents New Data on AXS-12 and Solriamfetol at SLEEP 2026 Conference - Quiver Quantitative
Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026 - Yahoo! Finance Canada
Axsome Therapeutics (AXSM) Stock Analysis: 57% Revenue Growth Propels Exciting Prospects - DirectorsTalk Interviews
Landscape Capital Management L.L.C. Sells 3,983 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
First Turn Management LLC Has $37.79 Million Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Nicholas Investment Partners LP Purchases 42,907 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Eventide Asset Management LLC Sells 175,172 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
The Technical Signals Behind (AXSM) That Institutions Follow - Stock Traders Daily
Rhenman & Partners Asset Management AB Reduces Stake in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics, Inc. $AXSM Shares Sold by Summit Financial LLC - MarketBeat
Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock - Stocktwits
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Doximity (DOCS) and Axsome Therapeutics (AXSM) - The Globe and Mail
Axsome therapeutics director Roger Jeffs sells $141,655 in shares By Investing.com - Investing.com India
Axsome therapeutics director Roger Jeffs sells $141,655 in shares - Investing.com UK
Axsome Therapeutics, Inc. (AXSM) Latest Stock News & Headlines - Yahoo Finance
Agitation in Alzheimer's Disease Market to Register Immense Growth at a CAGR of 14.9% During the Forecast Period (2026-2036) | DelveInsight - PR Newswire
Axsome Therapeutics, Inc. $AXSM Shares Sold by Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. - MarketBeat
Jefferies raises Axsome stock price target to $380 on sales outlook By Investing.com - Investing.com South Africa
Jefferies raises Axsome stock price target to $380 on sales outlook - Investing.com Canada
Axsome Therapeutics (NASDAQ:AXSM) Reaches New 12-Month HighShould You Buy? - MarketBeat
Clearbridge Investments LLC Sells 11,341 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics readies Auvelity Alzheimer's agitation launch, expands CNS pipeline - MSN
Insider Selling: Axsome Therapeutics (NASDAQ:AXSM) Director Sells 643 Shares of Stock - MarketBeat
Axsome Therapeutics director Susan Mahony sells $145,017 in shares By Investing.com - Investing.com India
Axsome Therapeutics director Susan Mahony sells $145,017 in shares - Investing.com UK
Axsome therapeutics director Mark Coleman sells $160,107 in stock By Investing.com - Investing.com India
Axsome therapeutics director Mark Coleman sells $160,107 in stock - Investing.com
Axsome Therapeutics Inc (AXSM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):